It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape ...

The INTERCEPT study is being funded to the tune of €38 million (nearly $40 million) over the next five years and is described ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

The UK government has launched a £150 million ($185 million) procurement drive for artificial intelligence solutions that can ...

The mental health clinical trials market is expected to double to $4.27 billion in 2028, up from $2.15 billion in 2018, and ...

A collaboration between data scientists, clinical researchers, and community opticians in the UK is hoping to develop an ...

Cervical cancer is often highly treatable, with a five-year relative survival rate of 91% for localised, early-stage disease.

Trump has so far not targeted any of Biden's signature healthcare policies, including Medicare drug pricing negotiation ...

At the conference last week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer, who explained a bit more about what a dual-masked T-cell ...